ストックスクリーナーアプリを入手
2.50
0.81%
0.02
アフターアワーズ：
2.47
-0.03
-1.20%
Cytomx Therapeutics Inc (CTMX) 最新ニュース
CytomX Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
CytomX Therapeutics CEO Sells Shares to Meet Tax Obligations - TradingView
CytomX Therapeutics Approves Key Amendments at Annual Meeting - TipRanks
Stocks in play: Roots Corp. - The Globe and Mail
Two Sigma Investments LP Cuts Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Cisco Powers AI-Ready Data Centers, From Hyperscale to Enterprise - The Globe and Mail
GoldMining Announces Closing of Flow-Through Financing and Commences Exploration at Yellowknife Gold Project - The Globe and Mail
Ballard announces 1.5 MW fuel cell engine order for Sierra Northern Railway - The Globe and Mail
Northern Trust Corp Grows Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN
BMO Lowers Fees on Asset Allocation ETFs to Deliver Greater Value to Investors - The Globe and Mail
Millennium Management LLC Grows Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX stock soars to 52-week high, hits $2.66 By Investing.com - Investing.com South Africa
CytomX stock soars to 52-week high, hits $2.66 - Investing.com Australia
CytomX Therapeutics CEO Set for Jefferies Conference: Key Biologics Updates Coming - Stock Titan
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - The Manila Times
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
CytomX Therapeutics (CTMX) Maintains "Buy" Rating with $5.00 Price Target | CTMX Stock News - GuruFocus
CytomX begins trial of new melanoma treatment with Merck therapy By Investing.com - Investing.com South Africa
CytomX begins trial of new melanoma treatment with Merck therapy - Investing.com Australia
CytomX (CTMX) Advances Phase 1 Study with CX-801 for Metastatic Melanoma | CTMX Stock News - GuruFocus
CytomX Therapeutics Doses First Patient in Phase 1 Study of CX-801 Combined with KEYTRUDA® for Metastatic Melanoma - Nasdaq
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma - The Manila Times
Clinical Trial Breakthrough: CytomX's New Melanoma Drug Combines With Keytruda in Phase 1 Study - Stock Titan
Equities Analysts Set Expectations for CTMX Q2 Earnings - Defense World
What is HC Wainwright’s Estimate for CTMX FY2026 Earnings? - Defense World
CytomX upgraded at H.C. Wainwright on trial data for cancer drug - MSN
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by HC Wainwright - Defense World
CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
H.C. Wainwright raises CytomX stock to buy, target to $5.00 By Investing.com - Investing.com South Africa
CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler - GuruFocus
CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler | CTMX Stock News - GuruFocus
After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff - The Business Journals
CytomX stock upgraded at H.C. Wainwright (CTMX:NASDAQ) - Seeking Alpha
HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - Nasdaq
CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX - GuruFocus
H.C. Wainwright raises CytomX stock to buy, target to $5.00 - Investing.com
CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX Stock News - GuruFocus
HC Wainwright Upgrades CytomX Therapeutics to Buy From Neutral, Price Target is $5 - marketscreener.com
CytomX Therapeutics (CTMX) Price Target Doubled Following Promis - GuruFocus
CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX St - GuruFocus
CytomX Therapeutics (CTMX) Price Target Doubled Following Promising Trial Results | CTMX Stock News - GuruFocus
CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX Stock News - GuruFocus
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates - MSN
Institutional investors have a lot riding on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with 52% ownership - simplywall.st
CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials - Value The Markets
CytomX Therapeutics Secures $93.4 Million Through Stock Sale - TipRanks
CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? - Seeking Alpha
CytomX (CTMX) Exceeds Revenue Expectations and Advances CRC Drug Development | CTMX Stock News - GuruFocus
CytomX Therapeutics Reports Q1 2025 Results and Progress - TipRanks
CytomX Therapeutics: Q1 Earnings Snapshot - MySA
CytomX Therapeutics Inc earnings beat by $0.21, revenue topped estimates - Investing.com South Africa
Transcript : CytomX Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):